Table of Contents

Section 1: Anxiety Disorders
Chapter 1: Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder
Amanda Sun and Tobias Wasser
Chapter 2: Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia
Erin Habecker and Tobias Wasser

Section 2: Bipolar Disorder
Chapter 3: Lithium Plus Valproate Combination Versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE)
João Paulo De Aquino and Robert Beech
Chapter 4: Mood Stabilizer Monotherapy vs. Adjunctive Antidepressant for Bipolar Depression: The STEP-BD Trial
João Paulo De Aquino and Robert Beech
Chapter 5: Suicide Risk in Bipolar Disorder: Comparing Lithium, Divalproex, and Carbamazepine
Rachel Katz and Robert Beech
Chapter 6: The Long-term Natural History of Bipolar I Disorder
Zachary Engler and Robert Beech

Section 3: Child and Adolescent Disorders
Chapter 7: The Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder (MTA)
Michael Hochman, edited by Michael H. Bloch
Chapter 8: Adolescents with SSRI-Resistant Depression: The TORDIA Trial
Amalia Londono Tobon and Hanna Stevens
Chapter 9: Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
J. Corey Williams and Hanna Stevens
Chapter 10: Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety: CAMS
David Saunders, Jerome Taylor, and Andres Martin
Chapter 11: Predictors of Suicidal Events: The Treatment of Adolescent Suicide Attempters study (TASA)
Michael Maksimowski and Zheala Qayyum
Chapter 12: Cognitive Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents with OCD
Falisha Gilman and Zheala Qayyum
Chapter 13: Initial Treatment of Bipolar I Disorder in Children and Adolescents: The TEAM Trial
Stephanie Ng and Andres Martin
Chapter 14: The Treatment for Adolescents with Depression Study (TADS)
Zachary Engler and Zheala Qayyum

Section 4: Cognitive Disorders: Delirium/Dementia
Chapter 15: Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease: CATIE-AD
Adam Mecca and Rajesh R. Tampi
Chapter 16: Risk of Death with Atypical Antipsychotic Medications for Dementia
Adam Mecca and Rajesh R. Tampi
Chapter 17: Treatment of Delirium in Hospitalized AIDS Patients: A Double-Blind Trial of Haloperidol, Chlorpromazine, and Lorazepam
Amanda Sun and Rajesh R. Tampi
Chapter 18: Memantine in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil
Brandon M. Kitay and Rajesh R. Tampi

Section 5: Epidemiology
Chapter 19: Global Burden of Mental and Substance Use Disorders
Stephanie Yarnell and Ellen Edens
Chapter 20: Prevalence and Severity of Psychiatric Comorbidities: The National Comorbidity Survey Replication (NCS-R)
Stephanie Yarnell and Ellen Edens

Section 6: Insomnia
Chapter 21: Behavioral and/or Pharmacotherapy for Older Patients with Insomnia
Robert Ross and Rajesh R. Tampi

Section 7: Major Depressive Disorder
Chapter 22: Treatment of Depression in Patients with Alcohol or Drug Dependence: A Meta-Analysis
J. Corey Williams and Gustavo Angarita-Africano
Chapter 23: Suicidality in Pediatric Patients Treated with Antidepressant Drugs: FDA Meta-analysis
David Saunders and Michael H. Bloch
Chapter 24: National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program
Joseph Taylor and Robert Ostroff
Chapter 25: Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta-analysis
Joseph Taylor and Robert Ostroff
Chapter 26: Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Michael Maksimowski and Zheala Qayyum
Chapter 27: Sequenced Treatment Alternatives to Relieve Depression: STAR*D
Eric Lin and Pochu Ho
Chapter 28: Cognitive Therapy vs. Medication in the Treatment of Moderate to Severe Depression
Daniel Barron and Robert Ostroff

Section 8: Obsessive Compulsive Disorder
Chapter 29: Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive Disorder
Brandon M. Kitay and Michael H. Bloch
Chapter 30: Meta-analysis of the Dose-response relationship of SSRI's in adult patients with Obsessive Compulsive Disorder
Eunice Yuen and Michael H. Bloch

Section 9: Personality Disorders
Chapter 31: Psychotherapy for Borderline Personality Disorder: A Multiwave Study
David Grunwald, Erica Robinson, and Sarah Fineberg
Chapter 32: Dialectical Behavior Therapy vs. Community Treatment by Experts for Reducing Suicidal Behaviors Among Patients with Borderline Personality Disorder
David Saunders, Erica Robinson, and Sarah Fineberg
Chapter 33: Ten-Year Course of Borderline Personality Disorder: The Collaborative Longitudinal Personality Disorders Study
Kevin Johnson, Erica Robinson, and Sarah Fineberg

Section 10: Psychiatry in Primary Care
Chapter 34: Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study
Amalia Londono Tobon and Catherine Chiles
Chapter 35: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial
Nikhil Gupta and Catherine Chiles

Section 11: Women's Mental Health
Chapter 36: Buprenorphine vs. Methadone During Pregnancy: The MOTHER Trial
Rachel Wurmser and Kirstin Wilkins

Section 12: Schizophrenia
Chapter 37: QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients
Amanda Sun and Vinod H. Srihari
Chapter 38: Tardive Dyskinesia with Atypical vs. Conventional Antipsychotic Medications
Emma Lo and Cenk Tek
Chapter 39: Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1
Chadrick Lane and Mohini Ranganathan
Chapter 40: Clozapine for Treatment-Resistant Schizophrenia
Chadrick Lane and Vinod H. Srihari
Chapter 41: Effectiveness of clozapine vs. other atypical antipsychotics: Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE)
Eunice Yuen and Cenk Tek
Chapter 42: Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
Hamilton Hicks and Cenk Tek
Chapter 43: Switching Antipsychotics to Reduce Metabolic Risk: The CAMP Trial
Eric Lin and John Cahill
Chapter 44: Cost Utility of Atypical Antipsychotics: CUtLASS-1
Nikhil Gupta and John Cahill
Chapter 45: North American Prodrome Longitudinal Study
Nikhil Gupta and Vinod H. Srihari
Chapter 46: Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT)
Daniel Barron and Noah Capurso
Chapter 47: A Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
Stephanie Ng and Cenk Tek

Section 13: Substance Use Disorders
Chapter 48: Methadone Maintenance vs. Detoxification and Psychosocial Treatment for Opioid Dependence: The M180 Study
Hamilton Hicks and Srinivas Muvvala
Chapter 49: Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study
Kevin Johnson and Srinivas Muvvala
Chapter 50: Levomethadyl acetate vs. Buprenorphine vs. Methadone for Opioid Dependence
Robert Ross and Brian Fuehrlein

About the Author

Dr. Ish P. Bhalla earned his BS cum laude from Case Western Reserve University and his MD from the University of Toledo College of Medicine. He completed his psychiatry residency from Yale University and is currently a forensic psychiatry fellow at Yale. He plans to pursue a career in medical education, academic psychiatry, healthcare policy, and services research. He will be pursuing a health policy fellowship as a National Clinician Scholar at The University of
California, Los Angeles.

Dr. Rajesh R. Tampi is a Professor of Psychiatry at Case Western Reserve University School of Medicine and the Vice Chairman for Education and Faculty Development, Residency Program Director, and the Chief of Geriatric Psychiatry at MetroHealth, Cleveland, Ohio. He is also the President of the International Medical Graduates (IMG) Caucus of the American Psychiatric Association and the Secretary and Treasurer of the American Association for Geriatric Psychiatry (AAGP).

Dr. Vinod H. Srihari developed and oversees Yale University's Evidence-Based Mental Health curriculum, which has been recognized as a national model by the American Association of Directors of Psychiatric Residency Training (AADPRT). He continues to enjoy the challenge of using population based evidence in the care of individual patients, teaching and learning how to make better use of the evidence, and designing clinical research in response to public health challenges.